Analysis of Reportable Segments
Danaher Corp. operates in 3 segments: Biotechnology; Life Sciences; and Diagnostics.
Segment Profit Margin
Danaher Corp., profit margin by reportable segment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Biotechnology | 26.62% | 34.35% | 35.87% | 20.51% | — |
| Life Sciences | 16.93% | 20.10% | 20.24% | 18.34% | 20.16% |
| Diagnostics | 25.12% | 31.67% | 23.50% | 20.78% | 17.28% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Biotechnology | Biotechnology segment profit margin ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
| Life Sciences | Life Sciences segment profit margin ratio deteriorated from 2021 to 2022 and from 2022 to 2023. | |
| Diagnostics | Diagnostics segment profit margin ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Segment Profit Margin: Biotechnology
Danaher Corp.; Biotechnology; segment profit margin calculation
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating profit | 1,909) | 3,008) | 3,074) | 1,082) | —) |
| Sales | 7,172) | 8,758) | 8,570) | 5,276) | —) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 26.62% | 34.35% | 35.87% | 20.51% | — |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment profit margin = 100 × Operating profit ÷ Sales
= 100 × 1,909 ÷ 7,172 = 26.62%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Biotechnology | Biotechnology segment profit margin ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Segment Profit Margin: Life Sciences
Danaher Corp.; Life Sciences; segment profit margin calculation
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating profit | 1,209) | 1,414) | 1,293) | 972) | 1,401) |
| Sales | 7,141) | 7,036) | 6,388) | 5,300) | 6,951) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 16.93% | 20.10% | 20.24% | 18.34% | 20.16% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment profit margin = 100 × Operating profit ÷ Sales
= 100 × 1,209 ÷ 7,141 = 16.93%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Life Sciences | Life Sciences segment profit margin ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Segment Profit Margin: Diagnostics
Danaher Corp.; Diagnostics; segment profit margin calculation
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating profit | 2,406) | 3,436) | 2,313) | 1,538) | 1,134) |
| Sales | 9,577) | 10,849) | 9,844) | 7,403) | 6,562) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 25.12% | 31.67% | 23.50% | 20.78% | 17.28% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment profit margin = 100 × Operating profit ÷ Sales
= 100 × 2,406 ÷ 9,577 = 25.12%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Diagnostics | Diagnostics segment profit margin ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Segment Return on Assets (Segment ROA)
Danaher Corp., ROA by reportable segment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Biotechnology | 5.10% | 8.01% | 8.06% | 2.77% | — |
| Life Sciences | 5.09% | 8.05% | 6.54% | 9.89% | 6.26% |
| Diagnostics | 16.53% | 23.34% | 15.36% | 10.22% | 7.85% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Biotechnology | Biotechnology segment ROA deteriorated from 2021 to 2022 and from 2022 to 2023. |
| Life Sciences | Life Sciences segment ROA improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. | |
| Diagnostics | Diagnostics segment ROA improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Segment ROA: Biotechnology
Danaher Corp.; Biotechnology; segment ROA calculation
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating profit | 1,909) | 3,008) | 3,074) | 1,082) | —) |
| Identifiable assets | 37,421) | 37,536) | 38,118) | 39,086) | —) |
| Segment Profitability Ratio | |||||
| Segment ROA1 | 5.10% | 8.01% | 8.06% | 2.77% | — |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment ROA = 100 × Operating profit ÷ Identifiable assets
= 100 × 1,909 ÷ 37,421 = 5.10%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Biotechnology | Biotechnology segment ROA deteriorated from 2021 to 2022 and from 2022 to 2023. |
Segment ROA: Life Sciences
Danaher Corp.; Life Sciences; segment ROA calculation
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating profit | 1,209) | 1,414) | 1,293) | 972) | 1,401) |
| Identifiable assets | 23,730) | 17,572) | 19,768) | 9,833) | 22,381) |
| Segment Profitability Ratio | |||||
| Segment ROA1 | 5.09% | 8.05% | 6.54% | 9.89% | 6.26% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment ROA = 100 × Operating profit ÷ Identifiable assets
= 100 × 1,209 ÷ 23,730 = 5.09%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Life Sciences | Life Sciences segment ROA improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Segment ROA: Diagnostics
Danaher Corp.; Diagnostics; segment ROA calculation
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Operating profit | 2,406) | 3,436) | 2,313) | 1,538) | 1,134) |
| Identifiable assets | 14,552) | 14,722) | 15,054) | 15,042) | 14,442) |
| Segment Profitability Ratio | |||||
| Segment ROA1 | 16.53% | 23.34% | 15.36% | 10.22% | 7.85% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment ROA = 100 × Operating profit ÷ Identifiable assets
= 100 × 2,406 ÷ 14,552 = 16.53%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Diagnostics | Diagnostics segment ROA improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Segment Asset Turnover
Danaher Corp., asset turnover by reportable segment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Biotechnology | 0.19 | 0.23 | 0.22 | 0.13 | — |
| Life Sciences | 0.30 | 0.40 | 0.32 | 0.54 | 0.31 |
| Diagnostics | 0.66 | 0.74 | 0.65 | 0.49 | 0.45 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Biotechnology | Biotechnology segment asset turnover ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
| Life Sciences | Life Sciences segment asset turnover ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. | |
| Diagnostics | Diagnostics segment asset turnover ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Segment Asset Turnover: Biotechnology
Danaher Corp.; Biotechnology; segment asset turnover calculation
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Sales | 7,172) | 8,758) | 8,570) | 5,276) | —) |
| Identifiable assets | 37,421) | 37,536) | 38,118) | 39,086) | —) |
| Segment Activity Ratio | |||||
| Segment asset turnover1 | 0.19 | 0.23 | 0.22 | 0.13 | — |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment asset turnover = Sales ÷ Identifiable assets
= 7,172 ÷ 37,421 = 0.19
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Biotechnology | Biotechnology segment asset turnover ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Segment Asset Turnover: Life Sciences
Danaher Corp.; Life Sciences; segment asset turnover calculation
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Sales | 7,141) | 7,036) | 6,388) | 5,300) | 6,951) |
| Identifiable assets | 23,730) | 17,572) | 19,768) | 9,833) | 22,381) |
| Segment Activity Ratio | |||||
| Segment asset turnover1 | 0.30 | 0.40 | 0.32 | 0.54 | 0.31 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment asset turnover = Sales ÷ Identifiable assets
= 7,141 ÷ 23,730 = 0.30
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Life Sciences | Life Sciences segment asset turnover ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Segment Asset Turnover: Diagnostics
Danaher Corp.; Diagnostics; segment asset turnover calculation
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Sales | 9,577) | 10,849) | 9,844) | 7,403) | 6,562) |
| Identifiable assets | 14,552) | 14,722) | 15,054) | 15,042) | 14,442) |
| Segment Activity Ratio | |||||
| Segment asset turnover1 | 0.66 | 0.74 | 0.65 | 0.49 | 0.45 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment asset turnover = Sales ÷ Identifiable assets
= 9,577 ÷ 14,552 = 0.66
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Diagnostics | Diagnostics segment asset turnover ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Segment Capital Expenditures to Depreciation
Danaher Corp., capital expenditures to depreciation by reportable segment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Biotechnology | 0.41 | 0.40 | 0.36 | 0.22 | — |
| Life Sciences | 0.57 | 0.61 | 0.55 | 0.47 | 0.29 |
| Diagnostics | 0.95 | 0.65 | 1.05 | 0.74 | 0.75 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | Biotechnology | Biotechnology segment capital expenditures to depreciation ratio improved from 2021 to 2022 and from 2022 to 2023. |
| Life Sciences | Life Sciences segment capital expenditures to depreciation ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. | |
| Diagnostics | Diagnostics segment capital expenditures to depreciation ratio deteriorated from 2021 to 2022 but then improved from 2022 to 2023 not reaching 2021 level. |
Segment Capital Expenditures to Depreciation: Biotechnology
Danaher Corp.; Biotechnology; segment capital expenditures to depreciation calculation
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Capital expenditures, gross | 417) | 405) | 385) | 169) | —) |
| Depreciation and amortization of intangible assets | 1,026) | 1,002) | 1,059) | 761) | —) |
| Segment Financial Ratio | |||||
| Segment capital expenditures to depreciation1 | 0.41 | 0.40 | 0.36 | 0.22 | — |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment capital expenditures to depreciation = Capital expenditures, gross ÷ Depreciation and amortization of intangible assets
= 417 ÷ 1,026 = 0.41
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | Biotechnology | Biotechnology segment capital expenditures to depreciation ratio improved from 2021 to 2022 and from 2022 to 2023. |
Segment Capital Expenditures to Depreciation: Life Sciences
Danaher Corp.; Life Sciences; segment capital expenditures to depreciation calculation
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Capital expenditures, gross | 320) | 325) | 210) | 137) | 142) |
| Depreciation and amortization of intangible assets | 558) | 531) | 382) | 292) | 487) |
| Segment Financial Ratio | |||||
| Segment capital expenditures to depreciation1 | 0.57 | 0.61 | 0.55 | 0.47 | 0.29 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment capital expenditures to depreciation = Capital expenditures, gross ÷ Depreciation and amortization of intangible assets
= 320 ÷ 558 = 0.57
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | Life Sciences | Life Sciences segment capital expenditures to depreciation ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Segment Capital Expenditures to Depreciation: Diagnostics
Danaher Corp.; Diagnostics; segment capital expenditures to depreciation calculation
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Capital expenditures, gross | 546) | 382) | 644) | 447) | 434) |
| Depreciation and amortization of intangible assets | 577) | 590) | 614) | 602) | 583) |
| Segment Financial Ratio | |||||
| Segment capital expenditures to depreciation1 | 0.95 | 0.65 | 1.05 | 0.74 | 0.75 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment capital expenditures to depreciation = Capital expenditures, gross ÷ Depreciation and amortization of intangible assets
= 546 ÷ 577 = 0.95
| Segment financial ratio | Reportable segment | The company |
|---|---|---|
| Segment capital expenditures to depreciation | Diagnostics | Diagnostics segment capital expenditures to depreciation ratio deteriorated from 2021 to 2022 but then improved from 2022 to 2023 not reaching 2021 level. |
Sales
Danaher Corp., sales by reportable segment
US$ in millions
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Biotechnology | 7,172) | 8,758) | 8,570) | 5,276) | —) |
| Life Sciences | 7,141) | 7,036) | 6,388) | 5,300) | 6,951) |
| Diagnostics | 9,577) | 10,849) | 9,844) | 7,403) | 6,562) |
| Environmental & Applied Solutions | —) | 4,828) | 4,651) | 4,305) | 4,399) |
| Total | 23,890) | 31,471) | 29,453) | 22,284) | 17,911) |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Operating profit
Danaher Corp., operating profit by reportable segment
US$ in millions
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Biotechnology | 1,909) | 3,008) | 3,074) | 1,082) | —) |
| Life Sciences | 1,209) | 1,414) | 1,293) | 972) | 1,401) |
| Diagnostics | 2,406) | 3,436) | 2,313) | 1,538) | 1,134) |
| Environmental & Applied Solutions | —) | 1,135) | 1,054) | 979) | 1,052) |
| Other | (322) | (305) | (269) | (340) | (318) |
| Total | 5,202) | 8,688) | 7,465) | 4,231) | 3,269) |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Depreciation and amortization of intangible assets
Danaher Corp., depreciation and amortization of intangible assets by reportable segment
US$ in millions
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Biotechnology | 1,026) | 1,002) | 1,059) | 761) | —) |
| Life Sciences | 558) | 531) | 382) | 292) | 487) |
| Diagnostics | 577) | 590) | 614) | 602) | 583) |
| Environmental & Applied Solutions | —) | 90) | 106) | 110) | 111) |
| Other | 5) | 9) | 7) | 10) | 9) |
| Total | 2,166) | 2,222) | 2,168) | 1,775) | 1,190) |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Identifiable assets
Danaher Corp., identifiable assets by reportable segment
US$ in millions
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Biotechnology | 37,421) | 37,536) | 38,118) | 39,086) | —) |
| Life Sciences | 23,730) | 17,572) | 19,768) | 9,833) | 22,381) |
| Diagnostics | 14,552) | 14,722) | 15,054) | 15,042) | 14,442) |
| Environmental & Applied Solutions | —) | 4,797) | 4,882) | 5,083) | 4,882) |
| Other | 8,785) | 9,723) | 5,362) | 7,117) | 20,376) |
| Total | 84,488) | 84,350) | 83,184) | 76,161) | 62,082) |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Capital expenditures, gross
Danaher Corp., capital expenditures, gross by reportable segment
US$ in millions
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Biotechnology | 417) | 405) | 385) | 169) | —) |
| Life Sciences | 320) | 325) | 210) | 137) | 142) |
| Diagnostics | 546) | 382) | 644) | 447) | 434) |
| Environmental & Applied Solutions | —) | 34) | 54) | 36) | 54) |
| Other | 100) | 6) | 1) | 2) | 4) |
| Total | 1,383) | 1,152) | 1,294) | 791) | 636) |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).